Scholarlink

Objective <p>The study examined the association between adiponectin levels and markers of Insulin Resistance (IR) in obese and non-obese adults with type 2 diabetes. Insulin Resistance was estimated using HOMA-IR, while group differences were assessed using appropriate statistical tests. Multiple linear regression was applied to evaluate associations between adiponectin and obesity indices while adjusting for HOMA-IR.</p> Results <p>Mean serum adiponectin did not differ significantly across obese diabetics, non-obese diabetics, and controls (5.9 ± 3.6&#xa0;µg/mL, 6.4 ± 3.2&#xa0;µg/mL, and 6.8 ± 3.5&#xa0;µg/mL, respectively; <i>p</i> = 0.13). Mean HOMA-IR values were comparable among obese diabetics (1.4 ± 2.1), non-obese diabetics (1.3 ± 1.0), and controls (1.1 ± 0.6). In multivariable regression models, serum adiponectin was not independently associated with obesity indices or HOMA-IR (all <i>p</i> &gt; 0.05). Serum adiponectin levels were not significantly different across the study groups, although numerically lower values were observed in obese individuals with diabetes. No significant relationship was found between adiponectin and clinical or biochemical markers of IR. These findings suggest that adiponectin may have limited utility as an isolated marker of IR in Nigerian adults with type 2 diabetes and underscore the need for larger, longitudinal studies to clarify its role.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Insulin resistance and serum adiponectin levels in Nigerian patients with type 2 diabetes mellitus: a case-control study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月18日

查看全文
  • Okechukwu Obumneme Ezekpo,
  • Tajudin Adesegun Adetunji,
  • David Olubukunmi Soyoye,
  • Gbadebo Oladimeji Ajani,
  • Oluwarotimi Bolaji Olopade,
  • Oluwafemi Andrew Ogunniyi,
  • Ayodeji Lamidi,
  • Rosemary Temidayo Ikem,
  • Babatope Ayodeji Kolawole

摘要

Objective

The study examined the association between adiponectin levels and markers of Insulin Resistance (IR) in obese and non-obese adults with type 2 diabetes. Insulin Resistance was estimated using HOMA-IR, while group differences were assessed using appropriate statistical tests. Multiple linear regression was applied to evaluate associations between adiponectin and obesity indices while adjusting for HOMA-IR.

Results

Mean serum adiponectin did not differ significantly across obese diabetics, non-obese diabetics, and controls (5.9 ± 3.6 µg/mL, 6.4 ± 3.2 µg/mL, and 6.8 ± 3.5 µg/mL, respectively; p = 0.13). Mean HOMA-IR values were comparable among obese diabetics (1.4 ± 2.1), non-obese diabetics (1.3 ± 1.0), and controls (1.1 ± 0.6). In multivariable regression models, serum adiponectin was not independently associated with obesity indices or HOMA-IR (all p > 0.05). Serum adiponectin levels were not significantly different across the study groups, although numerically lower values were observed in obese individuals with diabetes. No significant relationship was found between adiponectin and clinical or biochemical markers of IR. These findings suggest that adiponectin may have limited utility as an isolated marker of IR in Nigerian adults with type 2 diabetes and underscore the need for larger, longitudinal studies to clarify its role.